Alpha DNA Investment Management LLC Makes New Investment in Immunocore Holdings plc (NASDAQ:IMCR)

Alpha DNA Investment Management LLC acquired a new position in shares of Immunocore Holdings plc (NASDAQ:IMCR) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,213 shares of the company’s stock, valued at approximately $411,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IMCR. Primecap Management Co. CA raised its position in Immunocore by 26.7% in the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock valued at $76,954,000 after purchasing an additional 520,950 shares during the period. Armistice Capital LLC raised its position in Immunocore by 495.1% in the second quarter. Armistice Capital LLC now owns 976,000 shares of the company’s stock valued at $33,077,000 after purchasing an additional 812,000 shares during the period. Fiera Capital Corp raised its holdings in shares of Immunocore by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 875,593 shares of the company’s stock valued at $29,674,000 after buying an additional 9,181 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Immunocore by 14.5% in the 2nd quarter. Renaissance Technologies LLC now owns 646,920 shares of the company’s stock valued at $21,924,000 after buying an additional 82,120 shares during the period. Finally, Millennium Management LLC raised its holdings in shares of Immunocore by 124.4% in the 2nd quarter. Millennium Management LLC now owns 600,954 shares of the company’s stock valued at $20,366,000 after buying an additional 333,167 shares during the period. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Price Performance

NASDAQ IMCR opened at $32.28 on Monday. Immunocore Holdings plc has a fifty-two week low of $29.72 and a fifty-two week high of $76.98. The business has a fifty day moving average of $32.30 and a 200-day moving average of $37.36. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.50. The company had revenue of $80.25 million during the quarter, compared to analysts’ expectations of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The business’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.59) earnings per share. Equities research analysts predict that Immunocore Holdings plc will post -0.94 earnings per share for the current year.

Analysts Set New Price Targets

IMCR has been the topic of several research analyst reports. Barclays cut their price objective on Immunocore from $92.00 to $66.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. Oppenheimer restated an “outperform” rating and set a $89.00 price target (up previously from $87.00) on shares of Immunocore in a report on Friday, August 9th. UBS Group initiated coverage on Immunocore in a report on Thursday, October 24th. They set a “sell” rating and a $24.00 price target on the stock. Needham & Company LLC lowered their price objective on Immunocore from $78.00 to $71.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Finally, Mizuho cut Immunocore from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $72.00 to $38.00 in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Immunocore has an average rating of “Moderate Buy” and a consensus price target of $69.18.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.